UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates

Group 1 - Brendan, a Pennsylvanian, completed a Ph.D. in organic synthesis at Stanford University in 2009 [1] - He worked for Merck from 2009 to 2013 and has experience in biotech startups such as Theravance and Aspira before joining Caltech [1] - Brendan is a co-founder and the first employee of 1200 Pharma, which spun out of Caltech and received significant investment in the 8 figures [1] - He remains an avid investor focused on market trends, particularly in biotechnology stocks [1]